Chimeric Antigen Receptor T (CAR T) are T-cells that are genetically engineered and are used in cell therapy. Our expert team of scientists is committed to provide a wide range of services in CAR T-cell therapy research.
CAR Designing
- CAR discovery (scFv / vHH) and screening
- 2nd / 3rd / 4th generation CARs designing (ScFV /vHH / linkers/co-stimulatory domain testing / safety switches / standard designs)
- Dual/bi-specific CAR and universal / allogeneic CARs
CAR T Generation
- Viral vector system (lentivirus/retrovirus)
- Non-viral system (synthetic mRNA/ transposon)
- Transduction/transfection of primary T-cells from healthy donors
CAR T Manufacturing Process Optimization
- Media, cytokines and growth factors screening for ex vivo CAR T-cell manufacturing process optimization
CAR T Characterization
- CAR detection (% CAR+ T-cells) by flow cytometry
- Vector copy number (VCN) by ddPCR/ qRT-PCR
- Immunophenotyping (%CD3+/%CD4+, (%CD3+/%CD8+ CAR-T cells), %TN, %TSCM, %TCM, %TEM and %TE during and after ex vivo CAR-T expansion
- Activation (CD25) and exhaustion marker (PD-1, LAG-3, TIM3, CTLA-4) analysis
In vitro CAR T Screening
- CAR-T proliferation (recombinant protein or co-culture (E:T) assay)
- Cytotoxicity assay /co-culture (different E:T ratio) using target expressing parental or reporter cell lines
- T-cell activation (CD25) marker analysis
- T-cell exhaustion marker analysis (PD-1, LAG-3, TIM3, CTLA-4)
- Inflammatory cytokine profiling (IL-2, IFN-y and TNF-a, CD107 a/b)
In vivo CAR T Efficacy
- Tumor clearance study in orthotopic systemic NOD-SCID xenograft model (B-cell malignancies)
- Immunophenotyping of circulation CAR-T cells
- CAR-T activation, proliferation and persistence assessment by flow cytometry and Vector Copy Number (VCN) analysis
- Cytokine profiling (IL-2, IFN-y and TNF-a)
Reagent Generation for CAR T
- Lentivirus, retrovirus, synthetic mRNA, transposon system, KI/KO cell lines and reagent proteins
Why Aurigene Pharmaceutical Services?
CAR discovery
CAR designing and screening
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Accelerating Drug Discovery Through Innovative Partnerships
Genomics plays a vital role in identifying which gene is associated with a specific disease. A gene called CNOT1 is for example known for it's effect on brain development and for impairing memory and learning. Despite the great promise genomics provides in understanding the disease, genes are not the best drug targets....
Read More
Physiochemical Characterization Services
Backed by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives
2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
A Sensitive and a Simple RP-HPLC Method Development and Verification for the Quantitative Estimation of Cholecalciferolin Tablets
2005
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis [1]. It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization [2]. IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market